Go to Top

EntreMed, Inc. (ENMD): Initiation of a Second Site for its ENMD-2076 Study

EntreMed, Inc. (ENMD) announced today the initiation of a second site for its Phase 2 study of ENMD-2076 in triple-negative breast cancer (TNBC).

Kathy Miller, MD, Associate Professor at the Melvin and Bren Simon Cancer Center at Indiana University serves as the investigator for the study.

Indiana University joins the University of Colorado Cancer Center where the Phase 2 study is already underway. This study is sponsored by EntreMed and is supported by a grant from the National Cancer Institute.
More information about the clinical trial can be found at www.ClinicalTrials.gov.

About ENMD:

EntreMed, Inc., a clinical-stage pharmaceutical company, engages in developing therapeutics for the treatment of cancer. Its lead drug candidate is ENMD-2076, an Aurora A and angiogenic kinase inhibitor for the treatment of cancer, which is completing data for a multi-center Phase II study in patients with platinum resistant ovarian cancer, as well as a dual-institutional Phase II study in triple-negative breast cancer.